1. Home
  2. HIT vs SPRO Comparison

HIT vs SPRO Comparison

Compare HIT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIT
  • SPRO
  • Stock Information
  • Founded
  • HIT 1964
  • SPRO 2013
  • Country
  • HIT United States
  • SPRO United States
  • Employees
  • HIT N/A
  • SPRO N/A
  • Industry
  • HIT Specialty Insurers
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIT Finance
  • SPRO Health Care
  • Exchange
  • HIT Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • HIT 122.9M
  • SPRO 104.1M
  • IPO Year
  • HIT 2024
  • SPRO 2017
  • Fundamental
  • Price
  • HIT $2.76
  • SPRO $2.07
  • Analyst Decision
  • HIT Strong Buy
  • SPRO Buy
  • Analyst Count
  • HIT 1
  • SPRO 4
  • Target Price
  • HIT $2.50
  • SPRO $5.00
  • AVG Volume (30 Days)
  • HIT 942.3K
  • SPRO 713.7K
  • Earning Date
  • HIT 07-21-2025
  • SPRO 08-12-2025
  • Dividend Yield
  • HIT N/A
  • SPRO N/A
  • EPS Growth
  • HIT N/A
  • SPRO N/A
  • EPS
  • HIT 0.02
  • SPRO N/A
  • Revenue
  • HIT $26,692,318.00
  • SPRO $48,576,000.00
  • Revenue This Year
  • HIT $70.02
  • SPRO N/A
  • Revenue Next Year
  • HIT $63.39
  • SPRO N/A
  • P/E Ratio
  • HIT $132.57
  • SPRO N/A
  • Revenue Growth
  • HIT 29.68
  • SPRO N/A
  • 52 Week Low
  • HIT $0.51
  • SPRO $0.51
  • 52 Week High
  • HIT $7.59
  • SPRO $3.22
  • Technical
  • Relative Strength Index (RSI)
  • HIT 55.13
  • SPRO 48.98
  • Support Level
  • HIT $2.72
  • SPRO $1.83
  • Resistance Level
  • HIT $3.60
  • SPRO $1.94
  • Average True Range (ATR)
  • HIT 0.41
  • SPRO 0.10
  • MACD
  • HIT -0.11
  • SPRO 0.03
  • Stochastic Oscillator
  • HIT 14.48
  • SPRO 46.55

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: